ロード中...
Trastuzumab-induced cardiac dysfunction: A ‘dual-hit’
Trastuzumab (Trz) is a monoclonal antibody against the human epidermal growth factor receptor 2 that is found to be overexpressed in 25% to 30% of breast cancer patients. In spite of the therapeutic benefits of Trz, cardiotoxic side effects are still an issue. This effect is potentiated particularly...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Pulsus Group Inc
2011
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3209542/ https://ncbi.nlm.nih.gov/pubmed/22065936 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|